These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10560029)

  • 1. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.
    Friedman JI; Adler DN; Davis KL
    Biol Psychiatry; 1999 Nov; 46(9):1243-52. PubMed ID: 10560029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential noradrenergic targets for cognitive enhancement in schizophrenia.
    Friedman JI; Stewart DG; Gorman JM
    CNS Spectr; 2004 May; 9(5):350-5. PubMed ID: 15115947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanfacine treatment of cognitive impairment in schizophrenia.
    Friedman JI; Adler DN; Temporini HD; Kemether E; Harvey PD; White L; Parrella M; Davis KL
    Neuropsychopharmacology; 2001 Sep; 25(3):402-9. PubMed ID: 11522468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Trends in the Treatment of Schizophrenia.
    Meltzer HY
    CNS Neurol Disord Drug Targets; 2017; 16(8):900-906. PubMed ID: 28758583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
    Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N
    Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease.
    Robertson IH
    Neurobiol Aging; 2013 Jan; 34(1):298-308. PubMed ID: 22743090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental approaches to cognitive disturbance in Alzheimer's disease.
    Samuels SC; Davis KL
    Harv Rev Psychiatry; 1998; 6(1):11-22. PubMed ID: 10370429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease.
    Guzmán-Ramos K; Moreno-Castilla P; Castro-Cruz M; McGaugh JL; Martínez-Coria H; LaFerla FM; Bermúdez-Rattoni F
    Learn Mem; 2012 Sep; 19(10):453-60. PubMed ID: 22984283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.
    Thomsen MS; Hansen HH; Timmerman DB; Mikkelsen JD
    Curr Pharm Des; 2010 Jan; 16(3):323-43. PubMed ID: 20109142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.
    Livingston G; Walker AE; Katona CL; Cooper C
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):25-9. PubMed ID: 16801350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
    Lawrence AD; Sahakian BJ
    Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic strategies for augmenting cognitive performance in schizophrenia.
    Friedman JI; Temporini H; Davis KL
    Biol Psychiatry; 1999 Jan; 45(1):1-16. PubMed ID: 9894570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
    Friedman JI
    Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy.
    Phillips C; Fahimi A; Das D; Mojabi FS; Ponnusamy R; Salehi A
    Curr Alzheimer Res; 2016; 13(1):68-83. PubMed ID: 26391048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.